FDA approves Exelixis' Cabometyx for RCC

FDA approved an NDA from Exelixis Inc. (NASDAQ:EXEL) for a tablet formulation of Cabometyx cabozantinib ( XL184) as second-line therapy to treat

Read the full 222 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE